Study Summary: This study tests a new medicine called eloralintide for people with Obstructive Sleep Apnea (OSA) and who are either obese or overweight. OSA is a condition where breathing stops and starts during sleep. The study is split into two parts: YSA1 for people who can't or don't want to use a machine called Positive Airway Pressure (PAP), and YSA2 for those who have been using PAP for at least 3 months and will keep using it. The study will last approximately 76 weeks, which is about a year and a half.

• The study lasts about 76 weeks, so it's a long-term commitment.
• Participants will be grouped based on their use of PAP therapy.
• Several medical conditions and treatments, like diabetes and certain surgeries, make someone ineligible.